Core Viewpoint - The article emphasizes the importance of identifying and following leading stocks within a stable industry development framework, referred to as the "main line," which can last from 10 to 30 months. This approach is rooted in Mark's SEPA system and is crucial for effective investment strategies [1][3]. Group 1: Definition and Concept of Main Line - The term "main line" is defined as industry anchoring rather than short-term speculative trading. It represents a stable development trajectory in the market, contrasting with the day-to-day fluctuations of stock prices [1]. - The stock market is described as a chaotic system, where the main line serves as the underlying ordered structure amidst apparent randomness [2]. Group 2: Emergence of the Current Main Line - The article discusses the emergence of the current main line starting from September 24, highlighting that during significant market downturns, only a few stocks exhibit relative strength, indicating their potential as leading stocks [3]. - Examples of leading stocks during this period include Shuanglin Co., which showed resilience and continued to reach new highs even as the broader market declined [3][5]. Group 3: Unlocking Categories - The article outlines the process of unlocking various stock categories as the market recovers, with specific mentions of companies in the robotics and semiconductor sectors that led the charge during the recovery phase [6][9]. - Notable companies such as Hengxuan Technology and Lexin Technology are highlighted for their strong performance during market downturns, establishing them as early pioneers in their respective sectors [5][6]. Group 4: Consumer Sector Dynamics - The consumer sector is noted for its slower development in the first half of the year but is expected to have significant potential moving forward. Several companies in this sector have shown resilience and growth, particularly during market corrections [12]. - Examples include Zhongchong Co. and Marumi Biotech, which both reached new highs during the market's downturn, indicating strong underlying demand and potential for future growth [12]. Group 5: Investment Strategy Insights - The article advocates for a systematic approach to stock selection, focusing on observing resilient stocks during bear markets and tracking their performance over time, rather than engaging in random stock picking [13]. - It emphasizes the need for investors to develop a deep understanding of market dynamics and the ability to analyze and interpret data effectively to navigate the complexities of the stock market [13].

Core Insights - The analysis focuses on the inventory status of 14 representative listed companies in the daily chemical skincare sector for the year 2024, highlighting trends in inventory scale and turnover efficiency [1][2]. Inventory Scale and Proportion - Over half of the selected skincare companies experienced growth in inventory scale in 2024, with Chuang'er Biological showing the highest year-on-year increase of 62.44%, reaching an inventory scale of 0.35 billion [2][3]. - Other companies with significant inventory growth include Kesi Co. (0.97 billion, up 47.96%), Jinbo Biological (0.97 billion, up 45.68%), and Fulejia (1.6 billion, up 30.26%) [2][3]. - Water Sheep Co. has the highest inventory proportion relative to total assets at approximately 19.52% in 2024, indicating a notable increase from 19.32% in 2023 [4]. Inventory Turnover Efficiency - Among the analyzed companies, only Marubi and Qingsong Co. showed improvement in inventory turnover efficiency, while the remaining eight companies experienced an increase in inventory turnover days, indicating a decline in efficiency [1][5]. - Jinbo Biological, Huaxi Biological, and Beitaini reported inventory turnover days exceeding 270 days (approximately 9 months), with turnover days of 307.93 and 254.45 respectively for Jinbo and Huaxi [1][5]. - Eight out of the 14 companies improved their inventory turnover efficiency, while companies like Fulejia, Kesi Co., Marubi, Huaxi, Water Sheep, and Jiaheng Household experienced a decline in efficiency [7].

Group 1 - The core viewpoint is that the high sales expenses in the daily chemical skincare industry significantly erode profits, leading to high gross margins but low net margins [1][3] - In 2024, over half of the selected companies in the daily chemical skincare industry have a sales expense ratio exceeding 40%, indicating that they allocate more than 40% of their revenue to marketing [1] - Yatsen E-commerce has the highest sales expense ratio at 60.1%, followed by Shangmei Co. and Marubi Biotechnology with ratios of 58.11% and 55.04% respectively [1] Group 2 - Many listed companies in the daily chemical skincare industry invest heavily in marketing while underinvesting in research and development, leading to severe product homogeneity and insufficient innovation [3] - The heavy reliance on marketing has resulted in a price war within the industry, which diminishes profitability and creates a vicious cycle [3] - Companies like Betaini have become overly dependent on a single brand, with over 90% of their main business revenue coming from the "Winona" brand, which has seen a sales decline of 5.45% in 2024 [3] Group 3 - The challenge for many companies in the daily chemical skincare industry in 2025 will be to balance marketing and research and development expenditures, transitioning from a marketing-driven approach to a product-driven one [4]

Core Insights - The performance of the daily chemical skincare industry in 2024 is generally pessimistic, with only 6 out of 17 selected companies achieving both revenue and net profit growth [1][2][4] - Notably, 4 companies reported losses, including Yatsen E-commerce, Jiaheng Cosmetics, Furuida, and Shanghai Jahwa, with Yatsen E-commerce experiencing continuous losses since its IPO in 2020, totaling over 6.5 billion yuan in losses [1][2][4] Revenue and Profit Analysis - Among the 17 companies analyzed, 6 companies reported a decline in both revenue and net profit, including Qingsong Co., Kesi Co., Shuiyang Co., Furuida, and Huaxi Biological [4][5] - The companies with revenue and net profit growth include Jinbo Biological (revenue up 84.92%, net profit up 144.27%), Shangmei Co. (revenue up 62.1%), and Juzi Biological (revenue up 57.2%) [2][7][9] - Companies with revenue but no profit growth include Lafang Co. (revenue 889 million yuan, net profit down 36.84%), Beitaini (revenue 5.736 billion yuan, net profit down 33.53%), and Fulejia (revenue 2.017 billion yuan, net profit down 11.77%) [2][4] Losses Overview - Yatsen E-commerce reported total revenue of 3.393 billion yuan, a slight decline of 0.63%, with a net profit loss of 710 million yuan [5][6] - Shanghai Jahwa's revenue was 5.679 billion yuan, down 13.93%, with a net profit loss of 833 million yuan, marking a significant decline of 266.6% [5][6] - Jiaheng Cosmetics reported revenue of 923 million yuan, down 9.13%, with a net profit loss of 24 million yuan, a decline of 159% [5][6] Performance Rankings - The top three companies in revenue growth are Jinbo Biological, Shangmei Co., and Juzi Biological, with growth rates of 84.92%, 62.1%, and 57.2% respectively [7] - The bottom three in revenue growth are Shanghai Jahwa, Furuida, and Jiaheng Cosmetics, with declines of 13.93%, 13.02%, and 9.13% respectively [7] - In terms of net profit growth, the top three are Jinbo E-commerce, Shangmei Co., and Juzi Biological, with growth rates of 144.27%, 74%, and 42.4% respectively [9]

Core Viewpoint - The domestic beauty brand market in China is experiencing strong growth, driven by increasing consumer recognition and confidence in local brands, as stated by the CEO of Marubi Biotechnology during the 2024 annual and Q1 2025 earnings presentation [1] Financial Performance - Marubi Biotechnology achieved a net profit attributable to shareholders of 342 million yuan for the fiscal year 2024, representing a year-on-year increase of 31.69%, while the net profit after deducting non-recurring gains and losses was 327 million yuan, up 73.86% year-on-year [1] - In Q1 2025, the company reported a net profit attributable to shareholders of 135 million yuan, a year-on-year increase of 22.07%, with the net profit after deducting non-recurring gains and losses at 134 million yuan, up 28.57% year-on-year [1] - The stock price of Marubi Biotechnology has increased by over 150% since September 2024, with a closing limit up on May 15 [1] Strategic Transformation - The company has undergone a strategic transformation from a traditional beauty enterprise to a biotechnology beauty company, as indicated by the renaming of its stock from "Marubi Co., Ltd." to "Marubi Biotechnology" in 2024 [2] - Marubi Biotechnology emphasizes the importance of biotechnology in its current and future operations, particularly in the development and industrial application of key technologies such as recombinant collagen protein [2] Research and Development - In 2024, Marubi Biotechnology was recognized as a "National Research Center for Recombinant Functional Protein Technology," conducting 20 specialized studies on recombinant functional proteins throughout the year [2] - The company has made significant advancements in the development of various types of recombinant collagen proteins and has filed for 10 invention patents related to key technologies [2] Industry Trends - The beauty industry is witnessing accelerated penetration of advanced technologies such as artificial intelligence, synthetic biology, and smart manufacturing, which are driving industry upgrades [3] - Consumer demand is becoming more diverse and personalized, leading to higher expectations for quality, efficacy, and added value in beauty products and services [3] Sales and Distribution Strategy - Marubi Biotechnology is pursuing a multi-channel collaborative development strategy, with its brands already present in duty-free stores and actively exploring other channel opportunities [3]

Market Overview - On May 15, A-shares experienced a decline, with the Shanghai Composite Index falling by 0.68%, the Shenzhen Component Index by 1.62%, and the ChiNext Index by 1.91%. The total trading volume for the day was 1.19 trillion yuan [1]. Consumer Sector Performance - The consumer sector showed strong performance, particularly in the cosmetics segment, where no stocks declined. Notable stocks included Babai Co., which hit the daily limit with a 30% increase, and Qingsong Co. and Huaye Fragrance, both reaching a 20% increase [3][4]. - The apparel sector was also active, with Anzheng Fashion hitting the daily limit. The dairy sector saw strong gains, with Knight Dairy and Pinwo Foods among the top performers [3]. - The pet economy sector experienced fluctuations, with stocks like Meinong Biological reaching a 20% increase. Conversely, software development, communication services, and sectors like brokerage, military, and semiconductors faced corrections [3]. Investment Outlook - Pacific Securities indicated that the domestic consumption theme is gaining traction, particularly in the beauty and personal care sector, which is expected to see structural opportunities. The recovery of discretionary consumption, represented by branded apparel, is also on the rise. Short-term risk appetite is increasing, and companies that exceed recovery expectations may experience valuation corrections [3]. - Goldman Sachs raised its 12-month target for the MSCI China Index to 84 points and the CSI 300 Index to 4600 points, suggesting potential increases of 11% and 17%, respectively. The firm maintains an "overweight" rating on the Chinese stock market, favoring domestic-oriented sectors and recommending increased holdings in consumer goods, technology, and banking [3]. Cosmetics Industry Insights - According to the China Cosmetics Association, retail sales of cosmetics from major enterprises are projected to continue growing, reaching 114.9 billion yuan in Q1 2025, with a year-on-year increase of 3.20%. The top five trading platforms reported a Q1 retail sales figure of 152.885 billion yuan, marking a 14.68% increase year-on-year. Skincare products accounted for the largest share at 63.3%, with a growth of 16.02% [6]. Shipping and Port Sector - The European line shipping index rose by 8.72%, with mixed performances in the port and shipping sector. Notable gains were seen in stocks like China National Shipping, which surged over 25% during the day, and several other companies like Lianyungang and Nanjing Port hitting the daily limit [8][9]. - Citic Futures noted that the market may focus on inventory replenishment trading in the short term, while Xinda Securities anticipates a pulse-like increase in cargo volume on transcontinental routes as the traditional shipping peak season approaches [11].

Core Viewpoint - The 2024 Annual Shareholders' Meeting of Guangdong Marubi Biotechnology Co., Ltd. outlines the company's operational performance, strategic initiatives, and financial results, emphasizing growth in revenue and profit, alongside a focus on innovation and brand development in the beauty industry. Financial Performance - The company achieved a total revenue of 2.97 billion yuan in 2024, representing a year-on-year increase of 33.44% [29] - The main brand Marubi generated 2.06 billion yuan in revenue, up 31.69% year-on-year, while the PL brand reached 905 million yuan, a growth of 40.72% [31] - The gross profit margin improved to 73.7%, an increase of 3.01 percentage points, attributed to optimized product structure and cost control [31] - Net profit attributable to shareholders was 342 million yuan, up 31.69%, with a higher growth rate of 73.86% for net profit after excluding non-recurring gains and losses [31] R&D and Innovation - The company established a Life Sciences Center to explore new fields such as oral health and oral beauty, enhancing its R&D capabilities [8] - Marubi conducted 42 specialized research projects on raw materials, focusing on innovative plant extracts and bioengineering technologies [9] - The company received recognition as a "National Research Center for Recombinant Functional Proteins," highlighting its advancements in recombinant collagen technology [9] Brand Development - Marubi maintained its position as the top seller in the eye care category for three consecutive years, with the "Peptide Little Red Pen" eye cream achieving online sales of 533 million yuan, a 146% increase [12] - The PL brand successfully launched several products, with six foundation products each generating over 100 million yuan in annual GMV [14] - The company emphasized a dual-brand strategy, focusing on both Marubi and PL to drive growth and market presence [24] Marketing and Sales Strategy - The company implemented a multi-channel marketing strategy, achieving significant online sales growth, with online channels contributing 85.61% of total revenue [31] - Marubi's Tmall flagship store saw a 28% increase in sales, with a focus on enhancing user experience and member engagement [16] - The company utilized emotional and interactive marketing campaigns to strengthen brand recognition and consumer connection [13] Organizational Development - The company is committed to building a young, knowledgeable, and professional workforce, enhancing organizational agility and collaboration [20] - Marubi launched the "Marubi YOUNG Plan" to nurture new talent and improve overall employee capabilities [21] - The company emphasized a culture of innovation and teamwork through various creative activities and training programs [21]

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT Guangdong Marubi Biotechnology Co., Ltd. Table of Content | Message from Chairman | 03 | | --- | --- | | About Marubi | 05 | | Recap of 2024 | 11 | | ESG Governance | 15 | | Theme Spotlight: Scientific | 19 | | Skincare, Rejuvenating with | | | Collagen "Core" Innovation | | Appendix 97 | Key Performance Table | 97 | | --- | --- | | Indicators Index | 101 | | About This Report | 105 | Steady Operation, Forging Sustainable "Beauty" Power 01 People-Oriented, Composi ...

广东丸美生物技术股份有限公司 2024 年年度股东大会会议资料 广东丸美生物技术股份有限公司 2024 年年度股东大会 会议资料 2025 年 5 月 22 日 1 广东丸美生物技术股份有限公司 2024 年年度股东大会会议资料 广东丸美生物技术股份有限公司 2024 年年度股东大会会议须知 各位股东及股东代表： 为维护投资者的合法权益，确保广东丸美生物技术股份有限公司（以下简称"公 司"）2024 年年度股东大会的顺利召开，依据中国证券监督管理委员会《上市公司 股东大会规则》等有关规定，制定会议须知如下： 一、公司根据《公司法》《证券法》《上市公司股东大会规则》和《公司章程》的 规定，认真做好召开股东大会的各项工作。 二、公司董事会办公室具体负责会议有关程序方面的事宜。 三、为保证股东大会的严肃性和正常秩序，切实维护与会股东（包含股东代表， 下同）的合法权益，除出席会议的股东、公司董事、监事、高级管理人员、公司聘 请的律师及董事会邀请的人员外，公司有权依法拒绝其他人员进入会场。 四、出席会议的股东须在会议召开前 15 分钟到达会议现场向董事会办公室办理 签到手续，并请按规定出示股票账户卡、持股凭证、身份证或 ...

Group 1 - The core viewpoint of the article highlights the strong performance of the consumer sector, particularly in new consumption areas such as daily chemicals, health products, and pet economy, leading to significant stock price increases for companies like Huaye Spice and Baiyang Co. [1] - The article notes that several companies, including Jindawei, Xiwang Food, and Jiaoda Onl, have also seen their stock prices hit the daily limit, indicating a broad market trend in the consumer sector [1] - Institutions have pointed out that domestic new consumption enterprises are experiencing robust growth, driven by ongoing upgrades in aesthetics and spiritual satisfaction, particularly in emotional and experiential consumption [1]